Potential Impact of Rapid Multiplex PCR on Antimicrobial Therapy Guidance for Ventilated Hospital-Acquired Pneumonia in Critically Ill Patients, A Prospective Observational Clinical and Economic Study.


Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2022
Historique:
received: 29 10 2021
accepted: 14 03 2022
entrez: 2 5 2022
pubmed: 3 5 2022
medline: 4 5 2022
Statut: epublish

Résumé

To investigate the potential impact of the syndromic multiplex FilmArray Respiratory fluids from 100 adult patients with VHAP, receiving invasive mechanical ventilation in three intensive care units from one French university hospital, were tested prospectively using FAPP. Conventional cultures were performed in parallel as routine practice. Clinicians were left blinded to the FAPP results. Antimicrobial therapies based on FAPP results were simulated by independent blinded experts according to a predefined algorithm and compared to 1) those prescribed in practice according to local guidelines (real-life), and 2) those that complied with the international ERS/ESICM/ESCMID/ALAT recommendations. The primary endpoint was the number of days of broad-spectrum antimicrobial therapy. Secondary endpoints were the rates of microbiological treatment failure and cost-effectiveness ratio. The predicted median duration of broad-spectrum antibiotics was 0 [0-1.25] day in the FAPP-based simulation, versus 2 [0-6] days in real-life (p<0.0001) and 2 [2-3.25] days in the recommendations-based simulation (p<0.0001). Treatment failure was predicted in 3% of cases with FAPP results versus observed in 11% in real-life (p=0.08) and 6% with recommendations-based simulation (p=0.37). The incremental cost-effectiveness ratio was 1 121 € [-7021; 6794] to avoid one day of non-optimized antimicrobial therapy. Our results suggest that using FAPP in patients with VHAP has the potential to reduce the use of broad-spectrum antimicrobial therapy without increasing the risk of microbial treatment failure.

Identifiants

pubmed: 35493730
doi: 10.3389/fcimb.2022.804611
pmc: PMC9043525
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

804611

Informations de copyright

Copyright © 2022 Guillotin, Poulain, Gaborit, Bouras, Cinotti, Lakhal, Vourc’h, Rozec, Asehnoune, Vibet, Riche, Gibaud, Crémet and Roquilly.

Déclaration de conflit d'intérêts

Author BG was employed by Service de Maladies Infectieuses et Tropicales et CIC 1413. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Crit Care. 2020 Jul 14;24(1):434
pubmed: 32665030
Medicine (Baltimore). 2017 Jul;96(30):e7625
pubmed: 28746223
J Clin Microbiol. 2020 Jun 24;58(7):
pubmed: 32350045
Clin Infect Dis. 2021 Oct 5;73(7):e1601-e1610
pubmed: 32970811
Intensive Care Med. 2017 Oct;43(10):1464-1475
pubmed: 28733718
Lancet Infect Dis. 2014 Dec;14(12):1220-7
pubmed: 25455989
Eur Respir J. 2016 Apr;47(4):1219-28
pubmed: 26743488
Anaesth Crit Care Pain Med. 2018 Feb;37(1):83-98
pubmed: 29155054
Crit Care Med. 2018 Jul;46(7):1093-1098
pubmed: 29642107
Crit Care Med. 2005 Oct;33(10):2184-93
pubmed: 16215368
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
Diagn Microbiol Infect Dis. 2021 Jan;99(1):115183
pubmed: 33069002
Intensive Care Med. 2017 Nov;43(11):1613-1625
pubmed: 28374097
Antimicrob Agents Chemother. 2013 Mar;57(3):1488-95
pubmed: 23318796
Intensive Care Med. 2013 Apr;39(4):672-81
pubmed: 23358539
Lancet Infect Dis. 2013 Aug;13(8):665-71
pubmed: 23622939
Front Microbiol. 2020 Aug 25;11:2080
pubmed: 32983057
Clin Infect Dis. 2013 Nov;57(9):1237-45
pubmed: 23899684

Auteurs

Florian Guillotin (F)

Nantes Université, CHU Nantes, Anesthesie Réanimation, INSERM, Center for Research in Transplantation and Translational Immunology, Nantes, France.

Cécile Poulain (C)

Nantes Université, CHU Nantes, Anesthesie Réanimation, INSERM, Center for Research in Transplantation and Translational Immunology, Nantes, France.

Benjamin Gaborit (B)

Service de Maladies Infectieuses et Tropicales et CIC 1413, CHU Nantes, Nantes, France.

Marwan Bouras (M)

Nantes Université, CHU Nantes, Anesthesie Réanimation, INSERM, Center for Research in Transplantation and Translational Immunology, Nantes, France.

Raphaël Cinotti (R)

Service d' Anesthésie-Réanimation, Hôpital Nord Laënnec, CHU Nantes, Nantes, France.

Karim Lakhal (K)

Service d' Anesthésie-Réanimation, Hôpital Nord Laënnec, CHU Nantes, Nantes, France.

Mickael Vourc'h (M)

Service d' Anesthésie-Réanimation, Hôpital Nord Laënnec, CHU Nantes, Nantes, France.

Bertrand Rozec (B)

Service d' Anesthésie-Réanimation, Hôpital Nord Laënnec, CHU Nantes, Nantes, France.

Karim Asehnoune (K)

Nantes Université, CHU Nantes, Anesthesie Réanimation, INSERM, Center for Research in Transplantation and Translational Immunology, Nantes, France.

Marie-Anne Vibet (MA)

Plateforme de Méthodologie et Biostatistique, CHU de Nantes, Nantes, France.

Valéry-Pierre Riche (VP)

Cellule Innovation - Département Partenariat et Innovation - Direction de la Recherche, CHU de Nantes, Nantes, France.

Sophie-Anne Gibaud (SA)

Service de Bactériologie-Hygiène, Pôle de Biologie, CHU de Nantes, Nantes, France.

Lise Crémet (L)

Service de Bactériologie-Hygiène, Pôle de Biologie, CHU de Nantes, Nantes, France.

Antoine Roquilly (A)

Nantes Université, CHU Nantes, Anesthesie Réanimation, INSERM, Center for Research in Transplantation and Translational Immunology, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH